AUTHOR=Katz Leah M. , Ng Victor , Wu S. Peter , Yan Sherry , Grew David , Shin Samuel , Colangelo Nicholas W. , McCarthy Allison , Pass Harvey I. , Chachoua Abraham , Schiff Peter B. 

TITLE=Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.870143

DOI=10.3389/fonc.2022.870143

ISSN=2234-943X

ABSTRACT=Objectives: 
To investigate the efficacy and safety of lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) including oligorecurrent and oligoprogressive disease.

Methods: 
Single-institution retrospective analysis of 60 NSCLC patients with 62 discrete lesions treated with SBRT between 2008 and 2017. Patients were stratified into three groups, including oligorecurrent and oligoprogressive disease. Group 1, served as the control group, included local disease with no prior local therapy. Group 2 included recurrent disease (oligorecurrent disease) after local treatment of a primary lesion, and group 3: included regional or well-controlled distant metastatic disease receiving SBRT for a treatment naive lung lesion (oligoprogressive disease). Patient/tumor characteristics and adverse effects were recorded. Local failure free survival (LFFS), progression free survival (PFS), and overall survival (OS) were estimated using the Kaplan Meier method. 

Results:
At median follow-up of 34 months, 67% of the study population remained alive. The estimated 3-year LFFS for group 1, group 2, and group 3 patients was 95% (95% CI: 86%-100%), 82%(62% - 100%), and 83% (58-100%), respectively. The estimated 3-year PFS was 59% (42-83%), 40% (21%-78%), and 33% (12%-95%) , and the estimated 3-year OS was 74% (60-92%), 70% (49-100%), and 88% (67-100%)), respectively for each group. When adjusted for age and size of lesion, no significant difference in OS, LFFS, and PFS emerged between groups (p > 0.05). No patients experienced grade 3 to 5 toxicity. Twenty patients (33%) experienced grade 1 to 2 toxicity. The most common toxicities reported were cough, fatigue, and dysphagia 

Conclusions: 
Our data demonstrates control rates in group 1 patients comparable to historical controls. Our study also reveals comparable clinical results for SBRT in the treatment of NSCLC by demonstrating high rates of LFFS and OS in group 2 and group 3 patients with locally recurrent, locoregionally advanced, or well-controlled distant metastatic disease.

Advances in knowledge: 
Our research provides an additional data set proving the safety and efficacy of lung SBRT, as well as highlighting the novel clinical scenarios in which SBRT can be utilized to treat oligorecurrent and oligoprogressive disease.